{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anticancer", "VEGFR-2 inhibition", "apoptosis", "cell cycle", "immunomodulatory", "nicotinamide"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35980113", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "19"}, "DateRevised": {"Year": "2022", "Month": "09", "Day": "14"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/14756366.2022.2110868"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "37", "Issue": "1", "PubDate": {"Year": "2022", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: <i>in\u00a0vitro</i> and <i>in silico</i> studies.", "Pagination": {"StartPage": "2206", "EndPage": "2222", "MedlinePgn": "2206-2222"}, "Abstract": {"AbstractText": ["New nicotinamide derivatives <b>6</b>, <b>7</b>, <b>10</b>, and <b>11</b> were designed and synthesised based on the essential features of the VEGFR-2 inhibitors. Compound <b>10</b> revealed the highest anti-proliferative activities with IC<sub>50</sub> values of 15.4 and 9.8\u2009\u00b5M against HCT-116 and HepG2, respectively compared to sorafenib (IC<sub>50</sub> = 9.30 and 7.40\u2009\u00b5M). Compound <b>7</b> owned promising cytotoxic activities with IC<sub>50</sub> values of 15.7 and 15.5\u2009\u00b5M against the same cell lines, respectively. Subsequently, the VEGFR-2 inhibitory activities were assessed for the titled compounds to exhibit VEGFR-2 inhibition with sub-micromolar IC<sub>50</sub> values. Moreover, compound <b>7</b> induced the cell cycle cessation at the cycle at %G2-M and G0-G1phases, and induced apoptosis in the HCT-116. Compounds <b>7</b> and <b>10</b> reduced the levels of TNF-<i>\u03b1</i> by 81.6 and 84.5% as well as IL-6 by 88.4 and 60.9%, respectively, compared to dexamethasone (82.4 and 93.1%). <i>In silico</i> docking, molecular dynamics simulations, ADMET, and toxicity studies were carried out."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Elwan", "ForeName": "Alaa", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Gobaara", "ForeName": "Ibraheem M M", "Initials": "IMM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Mehany", "ForeName": "Ahmed B M", "Initials": "ABM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt."}], "LastName": "Eldehna", "ForeName": "Wagdy M", "Initials": "WM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Basic Science, Higher Technological institute, 10th of Ramadan City, Egypt."}], "LastName": "El-Metwally", "ForeName": "Souad A", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia."}], "LastName": "A Alsfouk", "ForeName": "Bshra", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "25X51I8RD4", "NameOfSubstance": "Niacinamide"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}], "MeshHeadingList": [{"QualifierName": ["metabolism", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Niacinamide"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": [], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7\u201330.", "ArticleIdList": ["31912902"]}, {"Citation": "Fabbro D, Parkinson D, Matter A.. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002;2:374\u201381.", "ArticleIdList": ["12127869"]}, {"Citation": "Abdallah AE, Mabrouk RR, Al Ward MMS, et al. . Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. J Enzyme Inhib Med Chem 2022;37:573\u201391.", "ArticleIdList": ["PMC8757611", "35012403"]}, {"Citation": "Phillips CM, Lima EA, Woodall RT, et al. . A hybrid model of tumor growth and angiogenesis: in silico experiments. PLoS One 2020;15:e0231137.", "ArticleIdList": ["PMC7147760", "32275674"]}, {"Citation": "Patel HM, Bari P, Karpoormath R, et al. . Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. RSC Adv 2015;5:56724\u201371."}, {"Citation": "Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013;153:13\u20139.", "ArticleIdList": ["PMC3528006", "23172303"]}, {"Citation": "Frezzetti D, Gallo M, Roma C, et al. . Vascular endothelial growth factor a regulates the secretion of different angiogenic factors in lung cancer cells. J Cell Physiol 2016;231:1514\u201321.", "ArticleIdList": ["26542886"]}, {"Citation": "Stuttfeld E, Ballmer\u2010Hofer K.. Structure and function of VEGF receptors. IUBMB Life 2009;61:915\u201322.", "ArticleIdList": ["19658168"]}, {"Citation": "El-Metwally SA, Abou-El-Regal MM, Eissa IH, et al. . Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg Chem 2021;112:104947.", "ArticleIdList": ["33964580"]}, {"Citation": "Shahin MI, Abou El Ella DA, Ismail NS, Abouzid KA.. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold. Bioorg Chem 2014;56:16\u201326.", "ArticleIdList": ["24922538"]}, {"Citation": "Yousef RG, Ibrahim A, Khalifa MM, et al. . Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J Enzyme Inhib Med Chem 2022;37:1389\u2013403.", "ArticleIdList": ["PMC9116259", "35577416"]}, {"Citation": "Elrazaz EZ, Serya RA, Ismail NS, et al. . Discovery of potent thieno [2, 3-d] pyrimidine VEGFR-2 inhibitors: design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. Bioorg Chem 2021;113:105019.", "ArticleIdList": ["34091286"]}, {"Citation": "Lee K, Jeong K-W, Lee Y, et al. . Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 2010;45:5420\u20137.", "ArticleIdList": ["20869793"]}, {"Citation": "Machado VA, Peixoto D, Costa R, et al. . Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg Med Chem 2015;23:6497\u2013509.", "ArticleIdList": ["26344591"]}, {"Citation": "Garofalo A, Goossens L, Six P, et al. . Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2011;21:2106\u201312.", "ArticleIdList": ["21353546"]}, {"Citation": "Dunlop RJ, Campbell CW.. Cytokines and advanced cancer. J Pain Symptom Manage 2000;20:214\u201332.", "ArticleIdList": ["11018340"]}, {"Citation": "Michalaki V, Syrigos K, Charles P, Waxman J.. Serum levels of IL-6 and TNF-\u03b1 correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312\u20136.", "ArticleIdList": ["PMC2409519", "15150588"]}, {"Citation": "Taher MY, Davies DM, Maher J.. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc Trans 2018;46:1449\u201362.", "ArticleIdList": ["30467123"]}, {"Citation": "Balkwill FJC. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25:409\u201316.", "ArticleIdList": ["16951987"]}, {"Citation": "Ungerstedt JS, Blomb\u00e4ck M, S\u00f6derstr\u00f6m T.. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003;131:48\u201352.", "ArticleIdList": ["PMC1808598", "12519385"]}, {"Citation": "Zeidan MA, Mostafa AS, Gomaa RM, et al. . Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Eur J Med Chem 2019;168:315\u201329.", "ArticleIdList": ["30826508"]}, {"Citation": "Hagras M, El Deeb MA, Elzahabi HS, et al. . Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation. J Enzyme Inhib Med Chem 2021;36:640\u201358.", "ArticleIdList": ["PMC7889231", "33588683"]}, {"Citation": "Ran F, Li W, Qin Y, et al. . Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: design, synthesis, and biological evaluation. Oxid Med Cell Longev 2021;2021:1\u201321.", "ArticleIdList": ["PMC8568530", "34745424"]}, {"Citation": "Zhang Q, Li J, Zhong H, Xu Y.. The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-\u03baB signal pathway. Mol Med 2021;27:1\u201311.", "ArticleIdList": ["PMC8451170", "34544355"]}, {"Citation": "Grange PA, Raingeaud J, Calvez V, Dupin N.. Nicotinamide inhibits propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-\u03baB and MAPK pathways. J Dermatol Sci 2009;56:106\u201312.", "ArticleIdList": ["19726162"]}, {"Citation": "He MM, Smith AS, Oslob JD, et al. . Small-molecule inhibition ofTNF-a. Science 2005;310:1022\u20135.", "ArticleIdList": ["16284179"]}, {"Citation": "Zia K, Ashraf S, Jabeen A, et al. . Identification of potential TNF-\u03b1 inhibitors: from in silico to in\u00a0vitro studies. Sci Rep 2020;10:1\u20139.", "ArticleIdList": ["PMC7708426", "33262408"]}, {"Citation": "Alanazi MM, Eissa IH, Alsaif NA, et al. . Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1760\u201382.", "ArticleIdList": ["PMC8344243", "34340610"]}, {"Citation": "El-Adl K, El-Helby A-GA, Sakr H, Elwan A.. [1, 2, 4] Triazolo [4, 3-a] quinoxaline and [1, 2, 4] triazolo [4, 3-a] quinoxaline-1-thiol-derived DNA intercalators: design, synthesis, molecular docking, in silico ADMET profiles and anti-proliferative evaluations. N J Chem 2021;45:881\u201397."}, {"Citation": "El-Adl K, El-Helby A-GA, Sakr H, Elwan A.. Design, synthesis, molecular docking and anti-proliferative evaluations of [1, 2, 4] triazolo [4, 3-a]. Quinoxaline Derivatives as DNA Intercalators and Topoisomerase II Inhibitors. Bioorg Chem 2020;105:104399.", "ArticleIdList": ["33113414"]}, {"Citation": "Chan KT, Meng FY, Li Q, et al. . Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Letters 2010;294:118\u201324.", "ArticleIdList": ["20153103"]}, {"Citation": "Sobhy MK, Mowafy S, Lasheen DS, et al. . 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: design, synthesis and biological evaluation. Bioorg Chem 2019;89:102988.", "ArticleIdList": ["31146197"]}, {"Citation": "Mena-Ulecia K, Tiznado W, Caballero J.. Study of the differential activity of thrombin inhibitors using docking, QSAR, molecular dynamics, and MM-GBSA. PLoS One 2015;10:e0142774.", "ArticleIdList": ["PMC4657979", "26599107"]}, {"Citation": "Wang S-Q, Shi M, Fang L, et al. . Design of dual inhibitors of human TNF-\u03b1 and IL-6 with potentials for the treatment of rheumatoid arthritis. Trop J Pharm Res 2019;18:2305\u201312."}, {"Citation": "Sousa SF, Fernandes PA, Ramos MJ.. Protein\u2013ligand docking: current status and future challenges. Proteins: Struct Funct Bioinformatics 2006;65:15\u201326.", "ArticleIdList": ["16862531"]}, {"Citation": "Hollingsworth SA, Dror RO.. Molecular dynamics simulation for all. Neuron 2018;99:1129\u201343.", "ArticleIdList": ["PMC6209097", "30236283"]}, {"Citation": "Hansson T, Oostenbrink C, van Gunsteren W.. Molecular dynamics simulations. Curr Opin Struct Biol 2002;12:190\u20136.", "ArticleIdList": ["11959496"]}, {"Citation": "Durrant JD, McCammon JA.. Molecular dynamics simulations and drug discovery. BMC Biol 2011;9:1\u20139.", "ArticleIdList": ["PMC3203851", "22035460"]}, {"Citation": "Genheden S, Ryde U.. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 2015;10:449\u201361.", "ArticleIdList": ["PMC4487606", "25835573"]}, {"Citation": "Chaitra G, Rohini R.. Synthesis and biological activities of [1, 3]\u2010oxazine derivatives. Der Pharma Chem 2018;10:96\u2013101."}, {"Citation": "Eldehna WM, Al-Rashood ST, Al-Warhi T, et al. . Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3\u03b2 inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies. J Enzyme Inhib Med Chem 2021;36:270\u201385.", "ArticleIdList": ["PMC7751407", "33327806"]}, {"Citation": "Al-Sanea MM, Al-Ansary GH, Elsayed ZM, et al. . Development of 3-methyl/3-(morpholinomethyl) benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J Enzyme Inhib Med Chem 2021;36:987\u201399.", "ArticleIdList": ["PMC8128204", "33985397"]}, {"Citation": "Abou-Seri SM, Eldehna WM, Ali MM, Abou El Ella DA.. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in\u00a0vitro biological evaluation. Eur J Med Chem 2016;107:165\u201379.", "ArticleIdList": ["26590508"]}, {"Citation": "Wang J, Lenardo MJ.. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000;113:753\u20137.", "ArticleIdList": ["10671365"]}, {"Citation": "Eldehna WM, Hassan GS, Al-Rashood ST, et al. . Synthesis and in\u00a0vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem 2019;34:322\u201332.", "ArticleIdList": ["PMC6366416", "30722708"]}, {"Citation": "Lo KK-W, Lee TK-M, Lau JS-Y, et al. . Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg Chem 2008;47:200\u20138.", "ArticleIdList": ["18067284"]}, {"Citation": "Sabt A, Abdelhafez OM, El-Haggar RS, et al. . Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in\u00a0vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem 2018;33:1095\u2013107.", "ArticleIdList": ["PMC6022226", "29944015"]}, {"Citation": "Balah A, Ezzat O, Akool E-S.. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-\u03b2/Smad signaling pathway in rat liver. Int Immunopharmacol 2018;65:493\u2013502.", "ArticleIdList": ["30391882"]}, {"Citation": "Aborehab NM, Elnagar MR, Waly NE.. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF\u20107 human breast cancer cell line. J Biochem Mol Toxicol 2021;35:e22638.", "ArticleIdList": ["33002289"]}, {"Citation": "Elnagar MR, Walls AB, Helal GK, et al. . Functional characterization of \u03b17 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Eur J Pharmacol 2018;826:106\u201313.", "ArticleIdList": ["29501870"]}, {"Citation": "Ibrahim MK, Eissa IH, Alesawy MS, et al. . Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4 (3H)-one derivatives as potential PPAR\u03b3 and SUR agonists. Bioorg Med Chem 2017;25:4723\u201344.", "ArticleIdList": ["28720328"]}, {"Citation": "Suleimen YM, Jose RA, Suleimen RN, et al. . Jusanin, a new flavonoid from artemisia commutata with an in silico inhibitory potential against the SARS-CoV-2 main protease. Molecules 2022;27:1636.", "ArticleIdList": ["PMC8911936", "35268738"]}, {"Citation": "Alesawy MS, Elkaeed EB, Alsfouk AA, et al. . In silico screening of semi-synthesized compounds as potential inhibitors for SARS-CoV-2 papain-like protease: pharmacophoric features, molecular docking, ADMET, toxicity and DFT studies. Molecules 2021;26:6593.", "ArticleIdList": ["PMC8588135", "34771004"]}, {"Citation": "Suleimen YM, Jose RA, Suleimen RN, et al. . Isolation and In Silico Anti-SARS-CoV-2 papain-like protease potentialities of two rare 2-phenoxychromone derivatives from Artemisia spp. Molecules 2022;27:1216.", "ArticleIdList": ["PMC8879996", "35209006"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "18", "Hour": "8", "Minute": "22"}, {"Year": "2022", "Month": "8", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "18"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35980113", "PMC9466619", "10.1080/14756366.2022.2110868"]}}], "PubmedBookArticle": []}